Directorate Change

RNS Number : 1612Q

AstraZeneca PLC

29 July 2010

 



ASTRAZENECA PLC APPOINTS NEW NON-EXECUTIVE DIRECTOR

AstraZeneca today announced that Dr Bruce Burlington is to join the Board of Directors as a Non-Executive Director, with effect from 1 August 2010.  Dr Burlington will also become a member of the Board's Science Committee.

Dr Burlington spent 17 years of his career with the US Food and Drug Administration where he was Director, Center for Devices and Radiological Health 1993-1999; held three senior positions in the Center for Drug Evaluation and Research - Acting Deputy Director of Medical Affairs, 1992-1993; Acting Director, Office of Generic Drugs 1990-1991; and Deputy Director, Office of Drug Evaluation II - and was Director, Division of Biological Investigational New Drugs, Center for Biologics Evaluation and Research 1986-1989 and Medical Officer and Chief, Laboratory of Respiratory Viruses, Division of Virology, Center for Drugs and Biologics 1983-1986.

He subsequently held a series of senior executive positions at pharmaceutical company, Wyeth, including Executive Vice-President, Business Practices and Compliance 2006-2007; Executive Vice-President, Quality, Regulatory, Safety, Compliance & Audit 2003-2006; Senior Vice-President, Regulatory Affairs & Quality 2000-2003; and Senior Vice-President, Global Regulatory Affairs 1999-2000.

Dr Burlington is currently a consultant in the field of pharmaceutical product development and regulatory affairs, a Non-Executive Director of Cangene Corporation, and a member of the Scientific Advisory Boards of the International Medica Foundation and H. Lundbeck A/S.

No disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 of the UK Listing Authority's Listing Rules in respect of the appointment of Dr Burlington.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com

Media Enquiries UK:
Neil McCrae	[phone]  (24 hours)
Chris Sampson	[phone]  (24 hours)
Sarah Lindgreen	[phone]  (24 hours)
Abigail Baron	[phone]  (24 hours)
Investor Enquiries UK:
Jonathan Hunt	[phone]	mob: [phone]
Karl Hård	[phone]	mob: [phone]
Clive Morris	[phone]	mob: [phone]
Investor Enquiries US:
Ed Seage	[phone]	mob: [phone]
Jorgen Winroth	[phone]	mob: [phone]

29 July 2010

- ENDS -

 

END

 

 

BOASEMFSUFSSEIW